Utility of oral glucose tolerance test in predicting type 2 diabetes following gestational diabetes: Towards personalized care

doi:10.4239/wjd.v12.i10.1778

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3462)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-5) series.

Item

Count

PDF

261

WORD

105

HTML

1845

Tables (1-5)

191

Sum=2402

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

351

Download

709

Sum=1060

Oct 15, 2021 (publication date) through May 12, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Diabetes. Oct 15, 2021; 12(10): 1778-1788
Published online Oct 15, 2021. doi: 10.4239/wjd.v12.i10.1778

Utility of oral glucose tolerance test in predicting type 2 diabetes following gestational diabetes: Towards personalized care

Riad Abdel Latif Bayoumi, Amar Hassan Khamis, Muna A Tahlak, Taghrid F Elgergawi, Deemah K Harb, Komal S Hazari, Widad A Abdelkareem, Aya O Issa, Rakeeb Choudhury, Mohamed Hassanein, Jeyaseelan Lakshmanan, Fatheya Alawadi

Riad Abdel Latif Bayoumi, Aya O Issa, Rakeeb Choudhury, Department of Basic Medical Sciences, College of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai 123, United Arab Emirates

Amar Hassan Khamis, Department of Biostatistics, HBMDC, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai 123, United Arab Emirates

Muna A Tahlak, Taghrid F Elgergawi, Deemah K Harb, Komal S Hazari, Widad A Abdelkareem, Department of Obstetrics and Gynecology, Dubai Health Authority, Dubai 123, United Arab Emirates

Mohamed Hassanein, Fatheya Alawadi, Department of Endocrinology, Dubai Health Authority, Dubai 123, United Arab Emirates

Jeyaseelan Lakshmanan, Department of Biostatistics, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai 123, United Arab Emirates

Author contributions: Bayoumi RAL contributed to the conception and design of the study and is responsible for the contents of the article, he had full access to the data in the study, he takes responsibility for the integrity and accuracy of the analyses performed; Tahlak M, Elgergawi T, Harb D, Hazari K, Abdelkareem W, Hassanein M, and Awadi FA collected clinical data from patients’ records; Osama A conducted interviews with patients and collected data; Statistical support was provided by Khamis A and Lakshmanan J; All authors have performed interpretation of the data, critical revision of the article and approved the final version of the manuscript for publication.

Supported by the Al Jalila Foundation, No. AJF201545.

Institutional review board statement: The study was reviewed and approved for publication by Dubai Scientific Research Ethics Committee of Dubai Health Authority, with Reference No. DSREC: 12/2015_05; dated November 29, 2015.

Informed consent statement: Data were anonymously collected for each participant in the study.

Conflict-of-interest statement: The authors have nothing to declare.

Data sharing statement: The patients’ personal data in the Hospital Information System cannot be released. A summary can be obtained from the Principal Investigator.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Riad Abdel Latif Bayoumi, MBBS, PhD, Professor, Department of Basic Medical Sciences, College of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Building 14, Dubai Healthcare City, Dubai 123, Dubai. riad.bayoumi@mbru.ac.ae

Received: May 31, 2021
Peer-review started: May 31, 2021
First decision: June 24, 2021
Revised: July 5, 2021
Accepted: August 30, 2021
Article in press: August 30, 2021
Published online: October 15, 2021

Core Tip

Core Tip: The oral glucose tolerance test (OGTT) remains the gold standard for assessing the risk of postnatal diabetes in women with gestational diabetes mellitus (GDM). Both the fasting blood glucose and 2-h blood glucose tests could predict postpartum abnormal glycemic status following antenatal GDM. However, each test reflects a different pathophysiology and possible subtype of type 2 diabetes (T2D). If fasting serum insulin measurements are added to an OGTT, additional data generated could distinguish T2D pathophysiology and possible subtypes. Information obtained could be used to match the T2D subtype with relevant prevention programs such as frequent follow-ups, lifestyle modifications, and new treatment protocols.